Latest news and press releases about Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Price
| Price | $10.84 |
| Market Cap | $263M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 55.22 |
| Price / Book | 1.58 |
| EV / EBITDA | -99.55 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 2.92% |
| Return on Invested Capital | -1.82% |
| Return on Assets | 4.15% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALF · LOKV · MLAC · OYSE · RTAC · SIMA · TACH
Explore sector: Financial Services · Shell Companies
More sections of DMAA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks